[go: up one dir, main page]

MX2019002818A - Metodos para detectar anticuerpos neutralizantes anti-leptina. - Google Patents

Metodos para detectar anticuerpos neutralizantes anti-leptina.

Info

Publication number
MX2019002818A
MX2019002818A MX2019002818A MX2019002818A MX2019002818A MX 2019002818 A MX2019002818 A MX 2019002818A MX 2019002818 A MX2019002818 A MX 2019002818A MX 2019002818 A MX2019002818 A MX 2019002818A MX 2019002818 A MX2019002818 A MX 2019002818A
Authority
MX
Mexico
Prior art keywords
neutralizing antibodies
methods
detecting anti
leptin
leptin neutralizing
Prior art date
Application number
MX2019002818A
Other languages
English (en)
Inventor
Sailstad Jeffrey
Original Assignee
Aegerion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aegerion Pharmaceuticals Inc filed Critical Aegerion Pharmaceuticals Inc
Publication of MX2019002818A publication Critical patent/MX2019002818A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En el presente documento se encuentran los métodos para detectar anticuerpos neutralizantes de leptinas, incluyendo metreleptina, así como para identificar sujetos con dichos anticuerpos neutralizantes.
MX2019002818A 2016-09-12 2017-09-12 Metodos para detectar anticuerpos neutralizantes anti-leptina. MX2019002818A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662393632P 2016-09-12 2016-09-12
PCT/US2017/051232 WO2018049424A1 (en) 2016-09-12 2017-09-12 Methods of detecting anti-leptin neutralizing antibodies

Publications (1)

Publication Number Publication Date
MX2019002818A true MX2019002818A (es) 2019-08-29

Family

ID=61559769

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002818A MX2019002818A (es) 2016-09-12 2017-09-12 Metodos para detectar anticuerpos neutralizantes anti-leptina.

Country Status (18)

Country Link
US (4) US10775386B2 (es)
EP (2) EP3509624B1 (es)
JP (2) JP7139317B2 (es)
CN (1) CN110139663B (es)
BR (1) BR112019004715A2 (es)
CA (1) CA3036551A1 (es)
DK (1) DK3509624T3 (es)
EA (1) EA201990720A1 (es)
ES (1) ES2959990T3 (es)
FI (1) FI3509624T3 (es)
HR (1) HRP20231076T1 (es)
HU (1) HUE063647T2 (es)
MX (1) MX2019002818A (es)
PL (1) PL3509624T3 (es)
PT (1) PT3509624T (es)
RS (1) RS64850B1 (es)
SI (1) SI3509624T1 (es)
WO (1) WO2018049424A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10775386B2 (en) 2016-09-12 2020-09-15 Aegerion Pharmaceuticals, Inc. Methods of detecting anti-leptin neutralizing antibodies
WO2019241653A1 (en) * 2018-06-16 2019-12-19 Board Of Regents, The University Of Texas System Weight loss regimen
JP7474240B2 (ja) * 2018-08-03 2024-04-24 ブリストル－マイヤーズ スクイブ カンパニー 抗薬物抗体を検出するための方法
CN113785203A (zh) * 2019-05-13 2021-12-10 里珍纳龙药品有限公司 改进的竞争性配体结合测定
CN111983226A (zh) * 2020-03-25 2020-11-24 新加坡国立大学 SARSr-CoV抗体的检测

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314804A (en) * 1992-03-24 1994-05-24 Serim Research Corporation Test for Helicobacter pylori
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5580954A (en) 1995-01-31 1996-12-03 Eli Lilly And Company Anti-obesity proteins
US5605886A (en) 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5691309A (en) 1995-01-31 1997-11-25 Eli Lilly And Company Anti-obesity proteins
US5559208A (en) 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
WO1996023515A1 (en) 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5594101A (en) 1995-03-03 1997-01-14 Eli Lilly And Company Anti-obesity proteins
AU6028396A (en) 1995-06-07 1996-12-30 Amgen, Inc. Ob protein compositions and method
AU695934B2 (en) 1995-06-30 1998-08-27 Eli Lilly And Company Methods for treating diabetes
JP4173913B2 (ja) 1995-08-17 2008-10-29 アムジエン・インコーポレーテツド Ｏｂタンパク質組成物を用いて血中脂質レベルを減少させ又は減少した血中脂質レベルを維持する方法
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
EP1285664B1 (en) 1995-11-22 2010-01-20 Amgen Inc. Methods of increasing lean tissue mass using OB protein compositions
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
AU2670897A (en) 1996-04-04 1997-10-29 Amgen, Inc. Fibulin pharmaceutical compositions and related methods
AU4075897A (en) 1996-08-16 1998-03-06 Roger Lallone A leptin binding protein and its use in methods for diagnosing and treating abnormalities of the endogenous leptin pathway
WO1998008512A1 (en) 1996-08-30 1998-03-05 Amgen Inc. Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor
CA2266585A1 (en) 1996-09-20 1998-03-26 Hoechst Aktiengesellschaft Use of leptin antagonists for treating insulin resistance in type ii diabetes
KR100937550B1 (ko) 1996-12-20 2010-01-19 암젠 인코포레이티드 Ｏｂ 융합 단백질 조성물과 이 단백질의 제조 방법
ES2183351T3 (es) 1997-04-17 2003-03-16 Amgen Inc Composicones que comprenden conjugados de proteina ob humana activa estable con una cadena fc de inmunoglobulinas y metodos.
WO1998055139A1 (en) 1997-06-06 1998-12-10 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
PT1107793E (pt) 1998-08-10 2005-02-28 Amgen Inc Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
CA2344623A1 (en) 1998-10-02 2000-04-13 Amgen Inc. Method to determine a predisposition to leptin treatment
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
CA2359840C (en) 1999-02-12 2012-10-23 Amgen Inc. Glycosylated leptin compositions and related methods
WO2002074979A2 (en) * 2001-03-20 2002-09-26 Ortho-Clinical Diagnostics, Inc. Expression profiles and methods of use
JP2005506994A (ja) 2001-10-22 2005-03-10 アムジェン インコーポレイテッド ヒト脂肪組織萎縮症を処置するためのレプチンの使用および該処置のための素因決定方法
AU2003290563A1 (en) 2002-10-31 2004-05-25 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US20050214300A1 (en) * 2002-11-25 2005-09-29 Chiron Corporation Methods for treating cancer using Porimin as a target
WO2004078944A2 (en) * 2003-03-05 2004-09-16 Maine Medical Center Research Institute Thrombin, soluble jaggedi, and trap and growth of stem cells
JP4754352B2 (ja) * 2003-08-29 2011-08-24 株式会社リバース・プロテオミクス研究所 タンパク質の固定化方法
DE10353593A1 (de) * 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
US7320868B2 (en) * 2004-03-19 2008-01-22 Arieh Gertler Leptin binding domain compositions and methods thereto
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
CN101939022A (zh) 2007-11-14 2011-01-05 安米林药品公司 治疗肥胖以及肥胖相关疾病和病症的方法
GB201004058D0 (en) * 2010-03-11 2010-04-28 Consiglio Nazionale Ricerche Diagnostic assay for obesity and related disorders
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
US20130266963A1 (en) * 2011-07-06 2013-10-10 Nestec S.A. Assay for detecting neutralizing autoantibodies to biologic therapy
ES2732475T3 (es) 2011-07-08 2019-11-22 Aegerion Pharmaceuticals Inc Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
JP6756611B2 (ja) * 2013-10-31 2020-09-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 中和抗体を検出するための競合リガンド結合アッセイ
RU2737719C2 (ru) * 2015-02-27 2020-12-02 Ионис Фармасьютикалз, Инк. Модулирование экспрессии аполипопротеина с-iii (аросiii) у пациентов с липодистрофией
US10775386B2 (en) 2016-09-12 2020-09-15 Aegerion Pharmaceuticals, Inc. Methods of detecting anti-leptin neutralizing antibodies

Also Published As

Publication number Publication date
SI3509624T1 (sl) 2023-12-29
JP2022176209A (ja) 2022-11-25
ES2959990T3 (es) 2024-02-29
EP3509624A1 (en) 2019-07-17
EP4283304A3 (en) 2024-02-28
US20200378988A1 (en) 2020-12-03
PT3509624T (pt) 2023-08-28
BR112019004715A2 (pt) 2019-07-16
HRP20231076T1 (hr) 2023-12-22
US11709166B2 (en) 2023-07-25
JP7509834B2 (ja) 2024-07-02
FI3509624T3 (fi) 2023-10-18
EP3509624A4 (en) 2020-02-19
JP2019529904A (ja) 2019-10-17
US10775386B2 (en) 2020-09-15
EP4283304A2 (en) 2023-11-29
JP7139317B2 (ja) 2022-09-20
US20250155450A1 (en) 2025-05-15
US20180074073A1 (en) 2018-03-15
EA201990720A1 (ru) 2019-08-30
HUE063647T2 (hu) 2024-01-28
DK3509624T3 (da) 2023-11-13
CN110139663A (zh) 2019-08-16
US20230314447A1 (en) 2023-10-05
WO2018049424A1 (en) 2018-03-15
CN110139663B (zh) 2024-05-07
EP3509624B1 (en) 2023-08-09
RS64850B1 (sr) 2023-12-29
CA3036551A1 (en) 2018-03-15
PL3509624T3 (pl) 2024-03-25

Similar Documents

Publication Publication Date Title
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
MX2022009625A (es) Receptores de antigenos quimericos condicionalmente activos para celulas t modificadas.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
EA201891983A8 (ru) Комбинированная терапия антителами к cd73
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
PH12016501763B1 (en) Multispecific antibodies
TW201613962A (en) Fabs-in-tandem immunoglobulin and uses thereof
EA201692219A1 (ru) Способы получения противовирусных соединений
PH12016501366A1 (en) Novel anti-baff antibodies
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
IL281355B (en) Compositions, methods and kits for diagnosis of a gastroenteropancreatic neuroendocrine neoplasm
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
ZA201703510B (en) Antibodies, uses & methods
MX2019002818A (es) Metodos para detectar anticuerpos neutralizantes anti-leptina.
EA201691952A1 (ru) Композиции и методы, имеющие отношение к диагностике рака предстательной железы
MX375933B (es) Uso medico de compuestos de artemisinina y agonistas de gefirina.
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
TW201612191A (en) RSV-specific antibodies and functional parts thereof
EA201591709A1 (ru) 5-бром-индирубины
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
MX377276B (es) Profármacos de antagonista de (s)-1-fenil-2-(piridin-2-il) etanamina (nmda).